

**Technology Appraisal Committee Meeting (Committee A)**  
**Prospero House, 241 Borough High Street, London SE1 1GA**

**Minutes:** Confirmed

**Date and Time:** Tuesday 22 May 2018, 10:00 – 15:00

<b>Present:</b>	1. Professor Iain Squire (Vice-Chair)	Present for all notes
	2. Dr Graham Ash	Present for all notes
	3. Dr Jeremy Braybrooke	Present for all notes
	4. Dr Minal Bakhai	Present for notes 7 to 11
	5. Dr Steve Edwards	Present for all notes
	6. Mr Adrian Griffin	Present for all notes
	7. Professor John McMurray	Present for all notes
	8. Ms Pamela Rees	Present for all notes
	9. Dr Paul Robinson	Present for notes 1 to 3
	10. Mr Stephen Sharp	Present for all notes
	11. Dr Brian Shine	Present for all notes
	12. Dr John Watkins	Present for all notes
	13. Professor Olivia Wu	Present for all notes
	14. Mr John Cairns	Present for all notes
	15. Dr Rebecca Harmston	Present for all notes

**In attendance:**

Helen Knight	Acting Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Administrator, National Institute for Health and Care Excellence	Present for all notes
Juliet Kenny	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 6
Eleanor Donegan	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 6

Thomas Walker	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 7 to 11
Rebecca Albrow	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 11
Henry Edwards	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 7 to 11
Amy Grove	Warwick Evidence, Evidence Review Group	Present for notes 1 to 6
Lazaros Andronis	Warwick Evidence, Evidence Review Group	Present for notes 1 to 6
Daniel Gallacher	Warwick Evidence, Evidence Review Group	Present for notes 1 to 6
Sabine Grimm	Kleinjen Systematic Reviews, Evidence Review Group	Present for notes 7 to 11
Professor Peter Clark	Cancer Drugs Fund Clinical Lead	Present for all notes
Dr Alistair Ring	Clinical Expert, Consultant in Medical Oncology	Present for notes 1 to 3
Melanie Sturtevant	Patient Expert	Present for notes 1 to 3

**Non-public attendees:**

Alan Lamb	Technical Analyst, NICE	Present for notes 6 to 11
Thomas Strong	Technical Adviser, NICE	Present for notes 6 to 11
Joanna Richardson	Technical Adviser, NICE	Present for notes 1 to 3
Ria Skelton	Editor, NICE	Present for all notes
Adam Storrow	Business Analyst, NICE	Present for all notes
Ana Uribe-Ucheverry	Corporate Office Coordinator, NICE	Present for all notes
Lesley Hall	NIHRIO	Present for all notes
Sarah Prowse	NIHRIO	Present for all notes

## **Notes**

### **Any other Business**

1. None

### **Appraisal of pertuzumab for the adjuvant treatment of HER2-positive breast cancer [ID1192]**

#### **Part 1 – Open session**

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from Roche.
3. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.
  - 3.1. Dr Alistair Ring declared a personal specific financial interest as he has received honoraria for advisory boards from Roche and PUMA and for educational lectures from Roche. He also declared a non-personal specific financial interest as his institution has received research funding from PUMA.
    - 3.1.1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
  - 3.2. Dr Paul Robinson declared that his company have launched a biosimilar to trastuzumab, which is not a comparator, but decided to abstain from the decision making.
  - 3.3. No further conflicts of interest were declared for this appraisal.

#### **Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)**

4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
5. The committee decision was based on consensus.
6. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

## **Appraisal of pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [ID1062]**

### **Part 1 – Open session**

7. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from MSD.
8. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests
  - 8.1. Dr Paul Robinson declared a personal specific financial interest as his company is the manufacturer of pembrolizumab.
    - 8.1.1. It was agreed that this declaration would prevent him from participating in the meeting.
  - 8.2. No further conflicts of interest were declared for this appraisal.

### **Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)**

9. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
10. The committee decision was based on consensus.
11. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.